Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 7/20 | 1.00 |
| ▸ | GAA | P10253 | 6/20 | 1.00 |
| ▸ | SI | P14410 | 6/20 | 1.00 |
| ▸ | MGAM2 | Q2M2H8 | 6/20 | 1.00 |
| ▸ | NUDT1 | P36639 | 4/20 | 1.00 |
| ▸ | FASN | P49327 | 4/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 1.00 |
| ▸ | IDH1 | O75874 | 4/20 | 1.00 |
| ▸ | PGAM1 | P18669 | 3/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 3/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 2/20 | 1.00 |
| ▸ | TTR | P02766 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 1.00 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29460081 | 1.00 | MGAM (1.00) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL30634827 | 1.00 | MGAM (1.00) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL15007011 | 0.92 | MGAM (0.84) | MGAMGAASIMGAM2NUDT1 | |
| Norcowanin SCHEMBL12241932 | 0.91 | MGAM (0.82) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL12241934 | 0.90 | MGAM (0.81) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL12430368 | 0.90 | MGAM (0.81) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL3416398 | 0.90 | MGAM (0.81) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL13081216 | 0.88 | MGAM (0.79) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL3745323 | 0.88 | MGAM (0.83) | MGAMGAASIMGAM2NUDT1 | |
| SCHEMBL28181857 | 0.87 | NUDT1 (1.00) | MGAMGAASIMGAM2NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | claimed |
| EP-4533059-A1 | ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE | Stealth BioTherapeutics Inc. (US) | 2025-04-09 | — | — | EP | claimed |
| US-20250090621-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-03-20 | — | — | US | claimed |
| US-20250057805-A1 | METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-02-20 | — | — | US | claimed |
| WO-2024254164-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-12-12 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20240299486-A1 | ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-09-12 | — | — | US | claimed |
| WO-2023230322-A1 | ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-11-30 | — | — | WO | claimed |
| CN-115886004-B | Application of plant source natural product gamma-mangostin in antagonizing xanthomonas | 贵州大学 | 2023-07-21 | — | — | CN | claimed |
| CN-115886004-A | Application of plant-derived natural product gamma-mangostin in antagonism of xanthomonas | 贵州大学 | 2023-04-04 | — | — | CN | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4719404-A2 | METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE | Stealth BioTherapeutics Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2012032544-A2 | SPHAERANTHUS INDICUS DERIVED INGREDIENTS AND THEIR COMPOSITIONS FOR ENHACING PHYSICAL PERFORMANCE AND ENERGY LEVELS | LAILA NUTRACEUTICALS (IN) | 2012-03-15 | — | — | WO | disclosed |
| US-20100298423-A1 | NUTRACEUTICAL COMPOSITION FROM GARCINIA MANGOSTANA | LAILA NUTRACEUTICALS (IN) | 2010-11-25 | — | — | US | disclosed |
| US-20100292490-A1 | A PROCESS FOR PRODUCING GAMMA MANGOSTIN | LAILA NUTRACEUTICALS (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2009093259-A2 | A PROCESS FOR PRODUCING γ-MANGOSTIN | GOKARAJU GANGA RAJU (IN) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | NR2E3, ALDH1A2, PDE6D | MGAM 4027/4885GAA 2896/4885SI 290/4885 |
| US-20250090621-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | PDE6C, PDE6A, PDE6B | MGAM 1971/4885GAA 2047/4885SI 1825/4885 |
| US-20100292490-A1 | A PROCESS FOR PRODUCING GAMMA MANGOSTIN | SOST, CYP51A1, GNMT | MGAM 39/4885GAA 342/4885SI 201/4885 |
| US-20250057805-A1 | METHODS FOR ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF BEVEMIPRETIDE | MRGPRX2, MRGPRX4, MRGPRX1 | MGAM 136/4885GAA 891/4885SI 119/4885 |
| US-20240299486-A1 | ADDRESSING INJECTION SITE REACTIONS ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE | MRGPRX2, MRGPRX1, MRGPRX4 | MGAM 426/4885GAA 1690/4885SI 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.